New analysis Highlights Immunotherapy โCombinationsโ for Advancedโข Liverโ Cancer Quality of Life
A recent network meta-analysis suggests that immunotherapy-based combinations, โฃspecifically atezolizumab plus bevacizumab, offer the best combination of survival benefit and quality โof life (QoL)โข preservation โขfor patients withโ advanced hepatocellular carcinoma (HCC). The โresearch, published in JAMA oncology, compared several treatment โregimens currently used for this aggressive cancer.
researchers analyzed data from studiesโ evaluating treatments including atezolizumab plusโ bevacizumab,โ sintilimab plus IBI305, durvalumab plusโค tremelimumab, lenvatinib, sorafenib, and tislelizumab. The analysis focused โคon how โthese โtreatments impacted patient-reported โhealth-related QoL across six key areas: overall health status, physical functioning, โคfatigue, jaundice, pain, andโ abdominal swelling. QoL wasโ assessed using questionnaires to trackโค time to deteriorationโฃ in each domain.
To rank the treatments,researchersโค calculated Surface Under the Cumulative โRanking (SUCRA) scores. SUCRA scores range from 0 โคto โ1, representing the probabilityโฃ that aโ treatment is the best among thoseโ studied – a score of 1 indicating the best and 0 the worst.
Keyโฃ Findings:
Atezolizumab plus bevacizumab demonstrated the highest probability of delaying deterioration in four crucial QoLโค domains: global health status and QoL (SUCRA 0.85; hazard โขratio [HR] 0.63), โabdominal โswelling (SUCRA 0.950; HR 0.57), โขjaundice (SUCRA 0.895; HR 0.77),and pain (SUCRA 0.861; โฃHR 0.65). โค It was slightly surpassedโข by sintilimab plus โIBI305 in terms of likely overall survival benefit (SUCRA 0.873 vs 0.892, โฃrespectively).
Sintilimab plus โคIBI305 ranked second for pain (SUCRAโ 0.739; HR 0.73)โ and thirdโค for abdominalโข swelling (SUCRA 0.689; HR 0.78), fatigue (SUCRA 0.800; HR 0.63), and jaundice (SUCRA 0.582; HR 0.96).
Sorafenib โคmonotherapy consistently rankedโฃ lowestโฃ across domains related to pain, fatigue, physical โfunctioning, and overall health status.
Tislelizumab showed promise in preserving physical functioning and reducing fatigue,โ possibly offering a valuable alternative when โQoLโข is a primaryโข concern.
* Integrating qol data with overall survival data revealed that atezolizumab plus bevacizumab consistentlyโ outperformedโ all othre regimens, while lenvatinib โ and sorafenib monotherapy ranked at the bottom.
Theโ study,โข led by David James Pinato, MD, MRes, PhD, of Imperial College London Hammersmith Campus, concluded that immunotherapy-based combinations,โข particularly atezolizumab plus bevacizumab, provide the most favorable balance between survival and QoLโฃ for patients with advanced HCC.
Studyโค Limitations:
The researchers acknowledged several limitations, including reliance onโ aggregate data which limited detailed patient-level analysis. Differences in โคthe QoL assessment tools โคand definitions of deteriorationโค used across studies impacted comparability. The analysis โassumed independence โbetween survival and QoL. โ Furthermore, QoL data โฃwere not available for โall regimensโข due to inconsistent reporting.
Funding & Disclosures:
The study received funding from the European Society for โMedical Oncology, UK National Institute โfor Health andโ Care Research Imperial Biomedical Research Center, European Association for the Study of the Liver, cancer Research UK, and theโ European Union’s NextGenerationEU.Several authors reported financial relationships with various pharmaceutical companiesโข and other relevantโ organizations, as detailed inโฃ the original publication.